vs
ELECTRO SENSORS INC（ELSE）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是ELECTRO SENSORS INC的23.6倍（$65.1M vs $2.8M）。MESA LABORATORIES INC净利率更高（5.6% vs 3.7%，领先1.8%）。ELECTRO SENSORS INC同比增速更快（14.8% vs 3.6%）。过去两年ELECTRO SENSORS INC的营收复合增速更高（10.8% vs 5.1%）
Polar Electro Oy是一家芬兰制造商，专注研发生产运动训练电脑设备，在全球行业内颇具知名度，其最突出的成就是开发出了世界上首款无线心率监测仪，如今在运动健康监测领域拥有深厚的技术积累。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ELSE vs MLAB — 直观对比
营收规模更大
MLAB
是对方的23.6倍
$2.8M
营收增速更快
ELSE
高出11.2%
3.6%
净利率更高
MLAB
高出1.8%
3.7%
两年增速更快
ELSE
近两年复合增速
5.1%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8M | $65.1M |
| 净利润 | $103.0K | $3.6M |
| 毛利率 | 50.3% | 64.2% |
| 营业利润率 | -0.3% | 12.2% |
| 净利率 | 3.7% | 5.6% |
| 营收同比 | 14.8% | 3.6% |
| 净利润同比 | -48.8% | 316.6% |
| 每股收益（稀释后） | $0.03 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELSEMLAB
| Q4 25 | $2.8M | $65.1M | ||
| Q3 25 | $2.7M | $60.7M | ||
| Q2 25 | $2.4M | $59.5M | ||
| Q1 25 | $2.2M | $62.1M | ||
| Q4 24 | $2.4M | $62.8M | ||
| Q3 24 | $2.5M | $57.8M | ||
| Q2 24 | $2.2M | $58.2M | ||
| Q1 24 | $2.2M | $58.9M |
净利润ELSEMLAB
| Q4 25 | $103.0K | $3.6M | ||
| Q3 25 | $208.0K | $2.5M | ||
| Q2 25 | $59.0K | $4.7M | ||
| Q1 25 | $-64.0K | $-7.1M | ||
| Q4 24 | $201.0K | $-1.7M | ||
| Q3 24 | $238.0K | $3.4M | ||
| Q2 24 | $-4.0K | $3.4M | ||
| Q1 24 | $11.0K | $-254.6M |
毛利率ELSEMLAB
| Q4 25 | 50.3% | 64.2% | ||
| Q3 25 | 53.1% | 61.5% | ||
| Q2 25 | 51.2% | 62.0% | ||
| Q1 25 | 48.4% | 61.8% | ||
| Q4 24 | 49.6% | 63.3% | ||
| Q3 24 | 50.4% | 61.3% | ||
| Q2 24 | 47.2% | 64.0% | ||
| Q1 24 | 48.1% | 62.1% |
营业利润率ELSEMLAB
| Q4 25 | -0.3% | 12.2% | ||
| Q3 25 | 6.6% | 7.8% | ||
| Q2 25 | -0.1% | 5.1% | ||
| Q1 25 | -7.5% | 2.4% | ||
| Q4 24 | 1.3% | 9.2% | ||
| Q3 24 | 6.9% | 6.1% | ||
| Q2 24 | -4.8% | 9.6% | ||
| Q1 24 | -4.5% | -460.6% |
净利率ELSEMLAB
| Q4 25 | 3.7% | 5.6% | ||
| Q3 25 | 7.6% | 4.1% | ||
| Q2 25 | 2.5% | 8.0% | ||
| Q1 25 | -2.9% | -11.4% | ||
| Q4 24 | 8.4% | -2.7% | ||
| Q3 24 | 9.5% | 5.9% | ||
| Q2 24 | -0.2% | 5.8% | ||
| Q1 24 | 0.5% | -432.2% |
每股收益（稀释后）ELSEMLAB
| Q4 25 | $0.03 | $0.65 | ||
| Q3 25 | $0.06 | $0.45 | ||
| Q2 25 | $0.02 | $0.85 | ||
| Q1 25 | $-0.02 | $-1.30 | ||
| Q4 24 | $0.06 | $-0.31 | ||
| Q3 24 | $0.07 | $0.63 | ||
| Q2 24 | $0.00 | $0.62 | ||
| Q1 24 | $0.00 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.6M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $14.8M | $186.7M |
| 总资产 | $15.7M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ELSEMLAB
| Q4 25 | $10.6M | $29.0M | ||
| Q3 25 | $10.6M | $20.4M | ||
| Q2 25 | $10.2M | $21.3M | ||
| Q1 25 | $10.0M | $27.3M | ||
| Q4 24 | $10.0M | $27.3M | ||
| Q3 24 | $10.3M | $24.3M | ||
| Q2 24 | $9.9M | $28.5M | ||
| Q1 24 | $10.1M | $28.2M |
总债务ELSEMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益ELSEMLAB
| Q4 25 | $14.8M | $186.7M | ||
| Q3 25 | $14.7M | $178.5M | ||
| Q2 25 | $14.4M | $172.5M | ||
| Q1 25 | $14.3M | $159.8M | ||
| Q4 24 | $14.3M | $155.2M | ||
| Q3 24 | $14.1M | $161.5M | ||
| Q2 24 | $13.8M | $150.7M | ||
| Q1 24 | $13.8M | $145.4M |
总资产ELSEMLAB
| Q4 25 | $15.7M | $434.8M | ||
| Q3 25 | $15.7M | $430.4M | ||
| Q2 25 | $15.2M | $435.7M | ||
| Q1 25 | $15.1M | $433.3M | ||
| Q4 24 | $14.9M | $433.3M | ||
| Q3 24 | $15.0M | $454.1M | ||
| Q2 24 | $14.5M | $440.4M | ||
| Q1 24 | $14.5M | $446.8M |
负债/权益比ELSEMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0K | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 0.19× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流ELSEMLAB
| Q4 25 | $20.0K | $18.8M | ||
| Q3 25 | $395.0K | $8.2M | ||
| Q2 25 | $277.0K | $1.9M | ||
| Q1 25 | $-30.0K | $12.7M | ||
| Q4 24 | $-277.0K | $18.1M | ||
| Q3 24 | $362.0K | $5.3M | ||
| Q2 24 | $-158.0K | $10.7M | ||
| Q1 24 | $202.0K | $12.9M |
自由现金流ELSEMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | $389.0K | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | $-298.0K | $17.3M | ||
| Q3 24 | $358.0K | $3.5M | ||
| Q2 24 | $-184.0K | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率ELSEMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | 14.2% | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | -12.4% | 27.6% | ||
| Q3 24 | 14.3% | 6.0% | ||
| Q2 24 | -8.3% | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度ELSEMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | 0.2% | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 0.9% | 1.3% | ||
| Q3 24 | 0.2% | 3.1% | ||
| Q2 24 | 1.2% | 1.5% | ||
| Q1 24 | 0.0% | 0.9% |
现金转化率ELSEMLAB
| Q4 25 | 0.19× | 5.17× | ||
| Q3 25 | 1.90× | 3.32× | ||
| Q2 25 | 4.69× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | -1.38× | — | ||
| Q3 24 | 1.52× | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | 18.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELSE
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
